Ultrasonographic assessment of lipodystrophy in HIV-1-infected patients;Valutazione ecografica della lipodistrofia nei pazienti con infezione da HIV

Radiologia Medica

Volumn 114, Issue 1, 2009, Pages 141-151

  Grima, P F ^a   Chiavaroli, R ^a   Grima, P ^a  

^a Operative Unit of Infectious Diseases   (Italy)

Author keywords

HIV; Lipodystrophy; Ultrasonography

Indexed keywords

ADULT; ARM; ARTICLE; BODY MASS; CONTROLLED STUDY; ECHOGRAPHY; ELBOW; FACE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAABDOMINAL FAT; KIDNEY; LEG; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MASSETER MUSCLE; SUBCUTANEOUS FAT; TRANSDUCER; UMBILICUS; ZYGOMA;

ABDOMINAL FAT; ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SUBCUTANEOUS FAT; TIME FACTORS;

EID: 62949239843     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-008-0333-y     Document Type: Article

References (29)

1. F.J. Palella K.M. Delaney A.C. Moorman 1998 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient Study Investigators N Engl J Med 338 853 860
2. G. Behrens A. Dejam H. Schmidt 1999 Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors AIDS 13 F63 F70
3. A. Carr D.A. Cooper 2000 Adverse effects of antiretroviral therapy Lancet 356 1423 1430
4. A. Carr K. Samaras S. Burton 1988 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 F51 F58
5. K.A. Lichtenstein D.J. Ward A.C. Moorman 2001 Clinical assessment of HIV associated lipodystrophy in an ambulatory population AIDS 15 1389 1398
6. A. Schwenk 2002 Methods of assessing body shape and composition in HIV associated lipodystrophy Curr Opin Infect Dis 15 9 16
7. A. Carr K. Samaras A. Thorisdottir 1999 Diagnosis, prediction, and natural course of HIV-1 proteaseinhibitor-associated lipodistrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 2093 2099
8. E. Martinez L. Bianchi M.A. Garcia-Viejo 2000 Sonographic assessment of regional fat in HIV-infected people Lancet 356 1412 1413
9. T. Saint-Marc M. Partisani I. Poizot-Martin 2000 Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study AIDS 14 37 49
10. P.W.G. Mallon J. Miller D.A. Cooper A. Carr 2003 Prospective evaluation of the effect of antiretroviral therapy on body composition in HIV-1 infected men starting therapy AIDS 17 971 979
11. R. Gulizia A. Vercelli C. Gervasoni 2006 Controversy concerning role of ultrasonographic lipoatrophy assessments in HIV patients AIDS 20 789 790
12. G.J. Moyle L. Lysakova S. Brown 2004 A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection HIV Med 5 82 87
13. V. Asensi E.R. Martin-Roces J.A. Carton 2004 Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV-type 1 infected patients receiving highly active antiretroviral therapy Clin Infect Dis 39 240 247
14. V. Asensi E.R. Martin-Roces J. Collazos 2006 Association between physical and Echographic fat thickness assessments and a lipodystrophy grading scale in lipodystrophic HIV patients: pratical implications AIDS Res Hum Retroviruses 22 830 836
15. J. Blanch A. Rousaud E. Martinez 2002 Impact of lipodystrophy on the quality of life of HIV-1 infected patients J Acquir Immune Defic Syndr 31 404 407
16. F. Satler 2003 Body habitus changes related to lipodystrophy Clin Infect Dis 36 [Suppl2] S84 S90
17. I.B. Coress P.K. Nicholas C.A. McGibbon 2004 Weight change, body image, and quality of life in HIV disease: a pilot study Appl Nurs Res 17 292 296
18. R. Burgoyne E. Collins C. Wagner 2005 The relation between lipodystrophy associated body changes and measures of quality of life and mental health for HIV-positive adults Qual Life Res 14 981 990
19. D. Carey H. Wand A. Martin 2005 Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial AIDS 19 1325 1327
20. H. Zylberger B. Nalpas S. Pol 2000 Is there a relationship between hepatitis C virus infection and antiretroviral-associated lipoatrophy? AIDS 14 2055 2065
21. C. Torti A. Patroni C. Tinelli 2002 Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy J Acquir Immune Defic Syndr 29 315 317
22. A. Rodriguez-Guardado J.A. Maradona V. Asensi 2003 Hepatitis C in patients with HIV infection and lipodystrophy J Acquir Immune Defic Syndr 32 348 349
23. M.S. Sulkowski S.H. Mehta M. Torbenson 2005 Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus AIDS 6 585 592
24. S. Pol P. Lebray A. Vallet-Pichard 2004 HIV infection and hepatic enzyme abnormalities: intrincacies of the pathogenic mechanisms Clin Infect Dis 38 [Suppl2] S65 S72
25. K.D. Miller M. Cameron L.V. Wood 2000 Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases Ann Intern Med 133 192 196
26. I.S. Fortgang P.C. Belitsos R.E. Chaisson 1995 Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy Am J Gastroenterol 90 1433 1436
27. A. Lonardo L.E. Adinolfi P. Loria 2004 Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease Gastroenterology 126 586 597
28. S.H. Mehta R.D. Moore D.L. Thomas 2003 The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons J Acquir Immune Defic Syndr 33 577 584
29. R. Gulizia E. Brunetti C. Gervasoni 2005 Sonographic assessment of lipodystrophy in HIV-infected patients: some open questions Clin Infect Dis 40 323 324